4905S-10: S0819 NSCLC

SWOG 0819: Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Type of Study
Cancer (Oncology) - Lung
Swedish Cancer Institute
Short Description

Purpose: This randomized phase III trial is studying carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or recurrent non-small cell lung cancer.



Temporarily Closed
Principal Investigator
Gary Goodman, M.D.
Eligibility Notes
  • Histologically or cytologically confirmed non-small cell lung cancer, including any of the following subtypes:


    • Adenocarcinoma



    • Large cell carcinoma



    • Squamous cell carcinoma



    • Unspecified



  • Newly diagnosed stage IV disease OR recurrent disease after prior surgery and/or irradiation



  • Brain metastases allowed provided they have been controlled for ≥ 2 months after completion of treatment and there is no residual neurological dysfunction while off corticosteroids



  • Zubrod performance status 0-1



  • Must be willing to provide prior smoking history



  • Prior radiotherapy allowed provided patients have recovered from all associated toxicities at the time of study registration



  • No prior chemotherapy, cetuximab, gefitinib, erlotinib, or other investigational agents that target the EGFR pathway



  • No prior bevacizumab or VEGF-related agents



  • No prior chimerized or murine monoclonal antibody therapy



  • At least 28 days since prior surgery (thoracic or other major surgeries) or open biopsy and recovered

  • No concurrent major surgical procedures

More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
(206) 215-3086